In HBeAg-positive chronic hepatitis B, combined response at the end of treatment was 15.4% with thymosin alpha‑1 plus peginterferon and 12.0% with peginterferon alone, not significantly different.
In plain wordsIn HBeAg-positive chronic hepatitis B, adding thymosin alpha‑1 to peginterferon did not give a significantly higher combined response at the end of treatment.
- Peptide
- Thymosin alpha-1
- Outcome
- No significant changeCombined response at end of treatment
- Study
n = 51
- Comparator
- Peginterferon alfa-2a monotherapy
- Outcome group
- Antiviral activity · Infection
- Studied dose
- 1.6 mg twice a week · 12 weeksAs given in this study (human).
Measurements
- Combined response rate
- 15.4%
- combination
- Combined response rate
- 12%
- monotherapy
Source sentences
The rates of the combined response, defined as HBeAg seroconversion, HBV DNA suppression, and normalization of serum ALT, were 4/26 (15.4%) and 3/25 (12.0%) for the combination group and the monotherapy group at the end of treatment (p = 0.725)
2 context sentences(design, population, supporting numbers)
HBeAg-positive CHB patients were enrolled in this prospective, randomized, open-label study.
Fifty-one patients were assigned to either combination (26 patients; 180 μg of peginterferon α-2a weekly for 48 weeks and 1.6 mg of thymosin α-1 twice a week for the first 12 weeks) or monotherapy (25 patients; 180 μg of peginterferon α-2a weekly for 48 weeks) groups.